A case of renal cell carcinoma metastases to the neck after long-term latency in the setting of chronic lymphocytic leukemia progression
Main Article Content
Keywords
cancer dormancy, second malignancy, targeted therapy, late metastatic disease, lymphoid malignancy
Abstract
We report on a 71-year-old man with a three-year history of chronic lymphocytic leukemia (CLL) who underwent left-sided nephrectomy due to renal cell carcinoma (RCC) 16 years earlier. Because of the CLL progression, he was being treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen, when he started to complain of hoarseness and cough. Laryngological examination disclosed tumorous lesion involving right half of the larynx. On computed tomography (CT) scans numerous lesions in the neck region (e.g. larynx, thyroid gland) were revealed. RCC metastases were confirmed in the histopathological examination of the specimen from the larynx. Since the treatment with interferon alpha was intolerable, eight courses of multi-kinase inhibitor, sorafenib, were applied. Despite the initial regression, progressive disease was shown in post-treatment CT. At present, the patient is being treated with m-TOR inhibitor, everolimus.
Article Sidebar
Article Details
How to Cite
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.